Clinical potential of mass spectrometry-based proteogenomics
- 28 November 2018
- journal article
- research article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 16 (4) , 256-268
Abstract
Cancer genomics research aims to advance personalized oncology by finding and targeting specific genetic alterations associated with cancers. In genome-driven oncology, treatments are selected for individual patients on the basis of the findings of tumour genome sequencing. This personalized approach has prolonged the survival of subsets of patients with cancer. However, many patients do not respond to the predicted therapies based on the genomic profiles of their tumours. Furthermore, studies pairing genomic and proteomic analyses of samples from the same tumours have shown that the proteome contains novel information that cannot be discerned through genomic analysis alone. This observation has led to the concept of proteogenomics, in which both types of data are leveraged for a more complete view of tumour biology that might enable patients to be more successfully matched to effective treatments than they would using genomics alone. In this Perspective, we discuss the added value of proteogenomics over the current genome-driven approach to the clinical characterization of cancers and summarize current efforts to incorporate targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into the clinical laboratory to facilitate clinical proteogenomics.Keywords
This publication has 169 references indexed in Scilit:
- Urine proteomics for discovery of improved diagnostic markers of Kawasaki diseaseEMBO Molecular Medicine, 2012
- Peptide Immunoaffinity Enrichment Coupled with Mass Spectrometry for Peptide and Protein QuantificationClinics In Laboratory Medicine, 2011
- A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancerProteomics – Clinical Applications, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Reverse phase protein microarrays advance to use in clinical trialsMolecular Oncology, 2010
- Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometryJournal of Immunological Methods, 2009
- Perspectives of targeted mass spectrometry for protein biomarker verificationCurrent Opinion in Chemical Biology, 2009
- The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometryJournal of Immunological Methods, 2009
- Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkersAnalytical Biochemistry, 2007
- An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein databaseJournal of the American Society for Mass Spectrometry, 1994